Haleon plc (HLN) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Haleon plc (HLN) Healthcare & Pipeline Overview

Haleon plc is a prominent player in the consumer healthcare sector, specializing in over-the-counter products that address oral health, pain relief, and respiratory health, backed by a strong portfolio of trusted brands.

What Is the Investment Thesis for HLN?

Haleon plc is well-positioned for growth, supported by a market capitalization of $43.7B and a P/E ratio of 30.6, indicating solid earnings potential. The company boasts a profit margin of 12.6% and a gross margin of 61.5%, reflecting operational efficiency. Key growth catalysts include the increasing demand for over-the-counter healthcare products, driven by a global shift towards self-medication and preventive health. With a free cash flow of $1.34 billion, Haleon has the financial flexibility to invest in research and development, expand its product lines, and enhance its market reach. The ongoing trend of health consciousness among consumers is expected to further boost sales in Haleon's therapeutic areas, making it a compelling player in the consumer healthcare market.

Based on FMP financials and quantitative analysis

HLN Key Highlights

Market capitalization of $43.7B, indicating a strong market presence.

• P/E ratio of 30.6, reflecting potential for earnings growth.
• Profit margin of 12.6%, demonstrating effective cost management.
• Gross margin of 61.5%, exceeding industry averages, indicating strong pricing power.
• Free cash flow of $1.34 billion, providing resources for strategic investments.

Who Are HLN's Competitors?

HLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HLN's Key Strengths?

Strong brand portfolio with high consumer recognition.

• Robust financial performance with healthy profit margins.
• Global presence in diverse markets enhancing revenue streams.
• Commitment to innovation in product development.

What Are HLN's Weaknesses?

Dependence on a limited number of key brands for revenue.

• Vulnerability to regulatory changes affecting product approvals.
• Exposure to competitive pressures from larger pharmaceutical companies.
• Potential supply chain disruptions impacting product availability.

What Are the Key Risks for HLN?

Rich valuation — a P/E of 30.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Regulatory hurdles affecting product approvals.
• Intense competition impacting market share.
• Economic fluctuations influencing consumer spending.
• Supply chain disruptions affecting product availability.

What Are the Growth Opportunities for HLN?

• Expansion in Emerging Markets: Haleon is poised to capitalize on the growing demand for consumer healthcare products in emerging markets, where healthcare access is improving. Haleon's established brand presence and distribution networks will enable it to capture a larger market share in these regions over the next five years.
• Innovative Product Development: Haleon is investing in research and development to innovate new products that meet evolving consumer needs. With a focus on natural ingredients and sustainability, the company aims to launch several new products in the next 18 months. This strategy aligns with the growing trend of health-conscious consumers seeking effective and safe over-the-counter solutions, potentially increasing Haleon's market share in key therapeutic areas.
• Digital Transformation: The company is enhancing its digital capabilities to improve customer engagement and streamline operations. By leveraging e-commerce platforms and digital marketing strategies, Haleon aims to increase its online sales, which currently represent a growing segment of the consumer healthcare market. This digital push is expected to contribute to revenue growth over the next few years as consumer shopping habits continue to evolve.
• Strategic Partnerships: Haleon is exploring strategic partnerships and collaborations to enhance its product offerings and market reach. By aligning with other health-focused companies, Haleon can expand its portfolio and leverage synergies in research and development. These partnerships are expected to yield new product launches and improve competitive positioning in the market over the next three years.
• Sustainability Initiatives: As consumers increasingly prioritize sustainability, Haleon is committed to reducing its environmental impact through sustainable sourcing and packaging. The company aims to achieve significant sustainability milestones by 2025, which will not only enhance its brand image but also attract environmentally conscious consumers, potentially driving sales growth.

What Threats Does HLN Face?

• Intense competition from established pharmaceutical and healthcare brands.
• Regulatory challenges that could impact product development timelines.
• Economic downturns affecting consumer spending on healthcare products.
• Shifts in consumer preferences towards alternative therapies.

What Are HLN's Competitive Advantages?

• Strong portfolio of trusted brands with high consumer loyalty.
• Established distribution networks across multiple regions.
• Significant investment in research and development for product innovation.
• Ability to adapt to consumer trends and preferences effectively.
• Operational efficiencies leading to strong profit margins.

What Does HLN Do?

Haleon plc, incorporated in 2021 and headquartered in Weybridge, United Kingdom, is a global leader in consumer healthcare, dedicated to the research, development, manufacture, and sale of a wide range of over-the-counter products. The company was formerly known as DRVW 2022 plc before rebranding to Haleon plc in February 2022. Haleon's extensive product portfolio includes therapeutic offerings in oral health, pain relief, respiratory health, and digestive health, alongside vitamins, minerals, and supplements. Notable brands under its umbrella include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Operating across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific, Haleon has established a significant presence in the consumer healthcare market. The company employs approximately 24,561 individuals, reflecting its commitment to innovation and quality in healthcare products. Haleon's focus on consumer needs and its strong brand recognition position it favorably within the competitive landscape of the healthcare industry.

What Products and Services Does HLN Offer?

• Research and develop consumer healthcare products.
• Manufacture a wide range of over-the-counter medications.
• Sell products across various therapeutic areas including oral health and pain relief.
• Provide vitamins, minerals, and supplements to promote overall wellness.
• Operate globally in multiple regions including North America and Europe.
• Manage a portfolio of well-known consumer healthcare brands.

How Does HLN Make Money?

• Generate revenue through the sale of over-the-counter healthcare products.
• Leverage strong brand recognition to maintain market share.
• Invest in research and development to innovate new products.
• Utilize strategic marketing to enhance product visibility and consumer engagement.
• Expand distribution networks to reach a broader customer base.

What Industry Does HLN Operate In?

The drug manufacturers sector, particularly in specialty and generic healthcare, is experiencing robust growth, driven by increasing consumer demand for self-care products. The global consumer healthcare market is projected to expand significantly, with a focus on preventive care and wellness. Haleon plc, with its diverse product offerings and strong brand portfolio, is strategically positioned to capitalize on these trends. The competitive landscape includes major players like Becton, Dickinson and Company (BDX), Cardinal Health, Inc. (CAH), and Takeda Pharmaceutical Company Limited (TAK), all of which contribute to a dynamic market environment.

Who Are HLN's Key Customers?

• Health-conscious consumers seeking over-the-counter solutions.
• Retail pharmacies and drugstores distributing healthcare products.
• Healthcare professionals recommending consumer healthcare brands.
• Global markets including North America, Europe, and Asia-Pacific.
• Consumers looking for vitamins, minerals, and supplements.

Wall Street analysts project Haleon plc revenue of about $11.43B for fiscal 2026, with EPS near $0.42. The estimate reflects 12 contributing analysts.

Haleon plc has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 23.8% above estimates on average.

Haleon plc's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.36 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Haleon plc stands at 6.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.2%, showing how much profit it generates from its asset base. HLN trades at a trailing price-to-earnings ratio of 30.57, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.92 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.3%, the inverse of the P/E and a quick read on earnings relative to price.

Haleon plc (HLN) Valuation Context

Valued at $43.7B, HLN is classified as a large-cap stock. Relative to its peer group, HLN's quantitative score of 49/100 is below the peer average of 70/100.

HLN Revenue & Earnings Trend

In Q2 2026, HLN generated $5.64B in top-line revenue, marking a sequential increase of 2.3%. The company recorded net income of $767.6M, with diluted EPS of $0.17. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, HLN averaged $0.16 in diluted EPS.

Company Profile

Haleon plc operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Weybridge, GB. The company is led by CEO Brian James McNamara. HLN has traded publicly since 2022.

HLN Financials

HLN Latest News

HLN Analyst Consensus

HLN MoonshotScore

HLN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources